
- /
- Supported exchanges
- / US
- / INBX.NASDAQ
Inhibrx Biosciences, Inc. (INBX NASDAQ) stock market data APIs
Inhibrx Biosciences, Inc. Financial Data Overview
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Inhibrx Biosciences, Inc. data using free add-ons & libraries
Get Inhibrx Biosciences, Inc. Fundamental Data
Inhibrx Biosciences, Inc. Fundamental data includes:
- Net Revenue: 200 K
- EBITDA: -229 863 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: -3.12
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Inhibrx Biosciences, Inc. News

Ligand Pharmaceuticals Stock Earns 84 RS Rating
Ligand Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84. Continue Reading View Comments


Liquidia Stock Gets Relative Strength Rating Lift
A Relative Strength Rating upgrade for Liquidia shows improving technical performance. Will it continue? Continue Reading View Comments

Arcutis Biotherapeutics Stock Scores RS Rating Upgrade
A Relative Strength Rating upgrade for Arcutis Biotherapeutics shows improving technical performance. Will it continue? Continue Reading View comments

Noteworthy Tuesday Option Activity: INBX, ODP, AZO
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Inhibrx Biosciences Inc (Symbol: INBX), where a total volume of 679 contracts has ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.